ナノキャリアのNK105
http://www.nanocarrier.co.jp/research/pipeline/01.html
優位性は有ったけど、主要評価項目は達成されなかったって、アカンだろ

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients
https://www.bioportfolio.com/news/article/3898910/A-multi-national-randomised-open-label-parallel-phase-III-non-inferiority-study.html
Conclusions
The primary endpoint was not met, but NK105 had a better PSN toxicity profile than PTX.